Your Source for Venture Capital and Private Equity Financings

BerGenBio Raises $12.5M US

2014-02-05
BERGEN, NORWAY, BerGenBio has raised $12.5 million to develop its portfolio of cancer therapies.
BerGenBio AS , an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013.

Proceeds from the financing will be used to support the development of the Company's portfolio of innovative cancer therapeutics. This includes the on-going clinical development of its lead drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which is currently in Phase Ib clinical studies to evaluate its safety and initial signs of efficacy to treat different cancers as a single agent and in combination with other drugs. The funds raised will be used to complete these studies, data from which is anticipated in 2015. BGB324 is the only selective Axl receptor tyrosine kinase inhibitor in clinical development to target tumor epithelial-mesenchymal transition (EMT) and has a potential application as a novel treatment for drug-resistant solid and hematological cancers, including non-small cell lung cancer and acute myeloid leukemia. The Company will also invest further in the drug candidate development of pipeline programs BGB001 and BGB002.

Richard Godfrey, CEO of BerGenBio, commented: 'I would like to thank our new and existing investors for their support. This important funding will enable us to advance our pipeline to key value inflection points. We believe that targeting Axl is a promising new approach to treating drug resistant cancers and we look forward to using this investment to continue exploring the clinical opportunity for our lead Axl inhibitor, BGB324, and our other candidate compounds.'

Sveinung Hole, Managing Partner of Sarsia Seed, commented: 'At the seed stage we recognised the huge addressable market potential for BerGenBio's EMT inhibitors and have continued to support the Company throughout its development. I am delighted the Company continues to attract funding and is able to progress its promising pipeline of novel targeted cancer therapies through further clinical development and realise significant value gain.

Ann-Tove Kongsnes, Investment Director, Investinor AS added: 'We are excited by the Company's prospects and are confident in the management team's ability to drive these programs forward.'

DNB Markets acted as sole bookrunner for the private placement.

The Axl tyrosine kinase receptor is regarded as one of the most promising new therapeutic targets for cancer drug development. It is upregulated in tumors residing in a hostile micro-environment and plays a crucial role in the epithelial-mesenchymal transition (EMT), which in turn is a key driver of metastasis (cancer spread) and in mechanisms of acquired drug-resistance.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading